The Republic of Equatorial Guinea achieved a high level of protection against malaria in clinical trials, according to the report “Sterile protections against human malaria in chemoattenuated PfSPZ vaccine” recently published in Nature.
The malaria vaccine, produced by Sanaria and tested in partnership with the Government of Equatorial Guinea, was found to immunize all subjects with three doses and protect against the disease when exposed more than ten weeks after the last dose.
Sanaria CEO, Stephen L. Hoffman, said the trials “will lead to an optimized vaccination regimen we expect to move rapidly into phase 3 clinical trials and licensure. Our goal is to use PfSPZ-CVac in mass vaccination programs to eliminate the malaria parasite and to prevent malaria in travelers.”
Equatorial Guinea began clinical trials at the end of 2016, along with other African countries Tanzania, Kenya, Mali, and Burkina Faso, as well as Germany and the U.S.
The Government of Equatorial Guinea, in partnership with Marathon Oil, Noble Energy, and Atlantic Methanol Production, three US energy companies, planned the trial.